Icaritin‐induced immunomodulatory efficacy in advanced hepatitis B virus‐related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival

Shukui Qin(Memorial Sloan Kettering Cancer Center), Yan Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Cheng(Jilin Province Tumor Hospital), Kun Meng(Hubei University of Arts and Science), Huimin Tao(Precision Research (United States)), Lian Li(Sun Yat-sen University), Qing Li(Xiangnan University), Shu Li(Jiujiang University), Bin Ye(Southern University of Science and Technology), Jun Liang(Qingdao University), Jun Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Zhaohui Wei, Limin Zheng(Weifang University of Science and Technology), Jian Xu(University of California, Los Angeles), Hao Ye(Sinotech Genomics (China)), Ying Fan(Academy of Medical Sciences)
Cancer Science
September 5, 2020
10.1111/cas.14641
Cited by 95

Related Papers

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2017|1.2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k